Chiltern International Ltd. and EPS INTERNATIONAL International Hold a Joint Seminar in Tokyo, Japan
Published: Mar 30, 2009
LONDON and TOKYO, March 27 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global Clinical Research Organization (CRO) that provides clinical development and staffing services in Europe, the Americas and India and its Asian partner EPS International Co. Ltd. (EPS INTERNATIONAL), a wholly owned subsidiary of EPS Co. Ltd., a leading provider of clinical development services in the Asian region, have jointly organized a seminar in Tokyo, Japan on 24th April 2009 to coincide with the 3rd anniversary of EPS International.
"We are very pleased to be part of the anniversary celebration of our partner EPS INTERNATIONAL in Japan," said Glenn Kerkhof, CEO of Chiltern. "With global consolidation in the pharma sphere, Asia is becoming an increasingly attractive market for clinical trial services. The Chiltern/EPS INTERNATIONAL partnership has been beneficial to both partners and helped continue to focus on the joint mission to deliver expert, high quality, clinical development services around the world."
"We are pleased to hold this seminar together with Chiltern International, a quality reputable global CRO having headquarters in the UK," said Tatsuhiko Ichiki, President & CEO of EPS INTERNATIONAL. "Through this seminar, it shows our commitment and expectation in this strategic collaboration enabling EPS INTERNATIONAL to expand geographical reach and attain global standard capability to best support our clients in the global drug development programs."
Chiltern provides services to EPS INTERNATIONAL from their network of offices throughout Europe, the Americas and India. Similarly, EPS INTERNATIONAL provides clinical development services for the Asian region from their offices in Japan, China, Singapore, Korea and Taiwan.
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1400 staff across 27 countries. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Further information is available at www.chiltern.com.
About EPS International:
EPS International Co. Ltd., a wholly owned subsidiary of a public listed company, EPS Co. Ltd. in Tokyo, Japan, commenced its business operations in April 2007. EPS INTERNATIONAL aims to provide a seamless clinical research and development platform through strategizing and synergizing its established research networks, valuable knowledge, know-how, resources and experiences in Asia region. EPS INTERNATIONAL is fully supported by a team of high caliber, diligent and dedicated clinical professionals having many years of experiences in managing large- and small-scale, global and local clinical trials covering from first-in-man to post marketing surveillance for new chemical entities, biologics and medical devices.
CONTACT: Mac McElroy, +1-423-968-9533, or fax, +1-423-968-3567,
firstname.lastname@example.org; or Stuart McGuire, +44-0-1753-512-000, or fax,
+44-0-1753-511-116, email@example.com, both of Chiltern
Web site: http://www.chiltern.com/